Document Detail


Longitudinal changes in central artery stiffness with lifestyle modification, washout, and drug treatment in individuals at risk for cardiovascular disease.
MedLine Citation:
PMID:  20367220     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We assessed 17 middle-aged and older individuals (58.0 +/- 7.9 years, 7 females) at risk for cardiovascular disease regarding: (1) Whether carotid artery stiffness (cAS) would be reduced with a 1-year lifestyle modification program, (2) to what degree cAS would return following washout (mean of 26.9 +/- 4.0 months) from the active intervention, and (3) whether a 24-week telmisartan treatment would reduce cAS more than our lifestyle modification program. cAS by Doppler ultrasound, cardiovascular disease risk factors, and exercise capacity were assessed at three points: Following the 1-year lifestyle modification, following the washout period, and following a 24-week telmisartan treatment. Following telmisartan, systolic blood pressure (SBP) was significantly decreased (114.8 +/- 12.3 mmHg) compared to baseline (127.9 +/- 12.7 mmHg) and following the washout period (126.1 +/- 14.9 mmHg). Similarly, diastolic blood pressure (DBP) was significantly lower following telmisaratn than following the washout period. Exercise capacity was increased following lifestyle modification but returned to the baseline level following the washout period. Following the lifestyle modification program, cAS was significantly reduced, and this reduction was maintained following the washout period. Conversely, the subsequent telmisartan treatment did not change cAS despite a significant blood pressure reduction. These results suggest that the reduced cAS achieved with lifestyle modification may not necessarily disappear following a cessation of the active program, indicating a possible role that family physicians can play in their clinical practice, and also providing a further rationale to promote lifestyle modification as an initial therapy for this population. In contrast, no additional benefit of telmisartan beyond our lifestyle intervention was observed in this study.
Authors:
Kunihiko Aizawa; J Kevin Shoemaker; Tom J Overend; Robert J Petrella
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolic syndrome and related disorders     Volume:  8     ISSN:  1557-8518     ISO Abbreviation:  Metab Syndr Relat Disord     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-11     Completed Date:  2010-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101150318     Medline TA:  Metab Syndr Relat Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  323-9     Citation Subset:  IM    
Affiliation:
Healthy Aging Group, Aging, Rehabilitation & Geriatric Care Research Centre, Lawson Health Research Institute at Parkwood Hospital, London, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Anthropometry
Blood Pressure / physiology
Cardiovascular Diseases / drug therapy*,  pathology*
Carotid Arteries / pathology*
Diet, Mediterranean
Exercise
Exercise Test
Female
Food Habits
Humans
Life Style*
Lipids / blood
Longitudinal Studies
Male
Middle Aged
Risk
Risk Factors
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Lipids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Walking in old age and development of metabolic syndrome: the health, aging, and body composition st...
Next Document:  Functional outcome of orthotopic bladder substitution: a comparison between the S-shaped and U-shape...